Department of Health Sciences, University of Florence, Anna Meyer Children's University Hospital, 50139 Florence, Italy.
Pediatric Diabetology Unit, Anna Meyer Children's University Hospital, 50139 Florence, Italy.
Nutrients. 2021 Oct 7;13(10):3517. doi: 10.3390/nu13103517.
Children and adolescents affected by type 1 diabetes have an increased risk of being overweight or obese and of suffering from cardiometabolic symptoms.
To retrospectively evaluate the effects of a new complex of polysaccharide macromolecules, Policaptil Gel Retard (PGR), on auxological and metabolic parameters, glycaemic variability and control parameters in paediatric patients with type 1 diabetes and metabolic syndrome (MetS).
Data for 27 paediatric patients with a diagnosis of type 1 diabetes in conjunction with obesity and MetS of at least 5 years' standing were collected and retrospectively studied. Of these, 16 (median age 12.9, range 9.5-15.8 years) had been adjunctively treated with PGR and 11 (median age 12.6, range 9.4-15.6 years) had not been treated with PGR. Auxological, metabolic and glycaemic control and variability parameters and insulin dosing were compared after 6 months in the two groups.
PGR significantly reduced BMI standard deviation score (SDS) ( < 0.005), waist SDS ( < 0.005), HbA1c ( < 0.05) and daily mean insulin dose requirement ( < 0.005). A significant improvement was also observed in the metabolic and glycaemic variability parameters of mean daily blood glucose (BG) levels ( < 0.005), SD of daily BG levels ( < 0.0001), mean coefficient of variation ( < 0.05), LBGI ( < 0.0001), HBGI ( < 0.0001), J-index ( < 0.005), total cholesterol ( < 0.005), HDL-cholesterol ( < 0.005) and LDL-cholesterol ( < 0.005) and triglycerides ( < 0.05).
PGR produces a good auxological and metabolic response in obese patients with MetS who are affected by type 1 diabetes. It led to a significant reduction in BMI SDS, waist SDS and an improvement in glucose control and variability as well as in other MetS parameters. The use of polysaccharide compounds, especially if associated with appropriate dietary changes, may help achieve treatment targets in type 1 diabetes and reduce the risk that patients develop metabolic syndrome.
1 型糖尿病患儿超重或肥胖以及出现心血管代谢症状的风险增加。
回顾性评估新的多糖大分子复合物 Policaptil Gel Retard（PGR）对患有 1 型糖尿病和代谢综合征（MetS）且肥胖的儿科患者的生长和代谢参数、血糖变异性和控制参数的影响。
收集了 27 名患有 1 型糖尿病且肥胖和 MetS 至少 5 年的儿科患者的数据，并进行了回顾性研究。其中 16 名（中位年龄 12.9 岁，范围 9.5-15.8 岁）接受了 PGR 辅助治疗，11 名（中位年龄 12.6 岁，范围 9.4-15.6 岁）未接受 PGR 治疗。比较两组患者治疗 6 个月后的生长、代谢和血糖控制及变异性参数和胰岛素剂量。
PGR 显著降低 BMI 标准差评分（SDS）（<0.005）、腰围 SDS（<0.005）、HbA1c（<0.05）和每日平均胰岛素剂量需求（<0.005）。代谢和血糖变异性参数中的平均每日血糖（BG）水平（<0.005）、每日 BG 水平的标准差（<0.0001）、平均变异系数（<0.05）、LBGI（<0.0001）、HBGI（<0.0001）、J-index（<0.005）、总胆固醇（<0.005）、高密度脂蛋白胆固醇（<0.005）、低密度脂蛋白胆固醇（<0.005）和甘油三酯（<0.05）也有显著改善。
PGR 对患有 1 型糖尿病和 MetS 的肥胖患者具有良好的生长和代谢反应。它显著降低了 BMI SDS、腰围 SDS，并改善了血糖控制和变异性以及其他 MetS 参数。使用多糖化合物，特别是如果与适当的饮食改变相结合，可能有助于实现 1 型糖尿病的治疗目标，并降低患者发生代谢综合征的风险。
Zotero 插件